Phase III Study of Evobrutinib in RMS (EVOLUTION MS2)

Treatment tested

• Evobrutinib

  Tyrosine-protein kinase BTK inhibitor

Compared with

• Interferon beta-1a

  Interferon alpha/beta receptor agonist

Placebo or sham

• Avonex® matched Placebo
• Evobrutinib matched Placebo

Other measures (23)

Inclusion Criteria: * Participants diagnosed with RMS (relapsing-remitting multiple sclerosis [RRMS] or secondary progressive multiple sclerosis [SPMS] with relapses) in accordance with 2017 Revised McDonald criteria (Thompson 2018). * Participants with one or more documented relapses within the 2 years before Screening with either: a. one relapse which occurred within the last year prior to randomization, OR b. the presence of at least 1 gadolinium-enhancing (Gd+) T1 lesion within 6 months prior to randomization. * Participants have EDSS score of 0 to 5.5 at Baseline. Participants with an EDSS score \<= 2 at screening are only eligible for participation if their disease duration (time since onset of symptoms) is no more than 10 years. * Participants are neurologically stable for >= 30 days prior to both screening and baseline. * Female participants must be neither pregnant nor breast-feeding and must lack child-bearing potential, as defined by either: post-menopausal or surgically sterile or use an effective method of contraception for the duration of the study. * Participants have given written informed consent prior to any study-related procedure. * Other protocol defined inclusion criteria could apply Exclusion Criteria: * Participants diagnosed with Progressive MS, in accordance with the 2017 Revised McDonald criteria as follows: a). Participants with Primary Progressive MS. b). Participants with secondary progressive MS without evidence of relapse. * Disease duration more than (>) 10 years in participants with an EDSS =\< 2.0 at screening. * Immunologic disorder other than MS, or any other condition requiring oral, intravenous (IV) , intramuscular, or intra-articular corticosteroid therapy, with the exception of well-controlled Type 2 diabetes mellitus or well controlled thyroid disease. * Other protocol defined exclusion criteria could apply.

The study was to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Interferon-beta-1a (Avonex®), once a week intramuscularly in participants with Relapsing Multiple Sclerosis (RMS).